Up 14% in a month, is the Resmed share price just getting started?

The sleep apnoea and respiratory company's shares have had a fine start to FY23.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Resmed shares have pushed higher in the new financial year
  • Healthcare has proven to be a defensive sector in these volatile times
  • In the past 12 months, the Resmed share price is down almost 6%

The ResMed Inc (ASX: RMD) share price has been a solid gainer this past month of trade, up almost 14% in that time.

The company's shares have travelled from a low of $27.63 apiece on 25 May to their current price of $32.34 a share.

Meanwhile, healthcare shares are rebounding in June-July, with the S&P/ASX 200 Health Care Index (ASX: XHJ) up 13% in a month as well. The year-to-date performances of both Resmed and the index are charted below:

TradingView Chart

Has the Resmed share price got more?

The broker Morgans is bullish on the Resmed share price and has a price target of $37.95.

In a recent note, the broker said its long-term view on the healthcare player is positive, despite market volatility.

It made note of Resmed's digital platform that addresses kinks along the "healthcare value chain" in its assessment.

Meanwhile, 64% of brokers rate Resmed as a buy right now, according to Refinitiv Eikon data. The remainder say it's a hold, with no sell ratings on the share.

The consensus price target from this list is $33.93, a fraction above its current share price.

Sector-wise, healthcare shares could catch further bids in FY23 if recent trends prevail.

Researchers at Deloitte recently noted a number of catalysts are pushing the "clinical, financial, and operational transformation" of health care – COVID-19 potentially being one of these.

Moreover, the sector is projected to deliver an average earnings per share (EPS) growth of 30% in the second half of CY2022, according to Bloomberg data.

In the past 12 months, the Resmed share price is down 5.7%, falling just over 9% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »